Garden Biopharmaceutical released the investor relations activity record, stating that in 2024, the company's product exports to the United States will account for 53% of the export value, with over 80% of the products not falling under the tariff increase scope effective April 2 in the United States. The company will actively communicate with customers and leverage its global market layout advantages to formulate effective response measures. The impact of tariffs on the company is limited